Advertisement

Oncology / Hematology General

IRGs Risk Stratification & Prognosis Prediction in LUSC

Oct 19, 2022

It was well established that inflammation has a complex association with carcinogenesis, tumor development, and the tumor immune microenvironment. However, little was known about how lung squamous car...

Acalabrutinib in Patients with R/R Marginal Zone Lymphoma (MZL)

Oct 19, 2022

In a side-by-side comparison study in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia, the Bruton tyrosine kinase inhibitor acalabrutinib showed enhanced selectivity and tolerabil...

Whole-body MRI Plus Serological Follow-up for Early Identification of Progression in SMM Patients

Oct 19, 2022

In order to enable early treatment and prevent the emergence of end-organ damage during the transition from smoldering multiple myeloma (SMM) to MM, the definition of multiple myeloma (MM) was modifie...

nMoAbs in Haematological Patients Aucisymptomatic for COVID-19

Oct 19, 2022

Patients with hematological malignancies (HM) continue to face COVID-19 as a pertinent problem. In those receiving active medical treatment, vaccinations have no effect. In the multicenter retrospe...

KRAS Mutated Non-Small Lung Carcinoma

Oct 18, 2022

KRAS has proved impossible to target despite being a frequent variation (~20% of non-small-cell lung cancer [NSCLC]), due to the molecular structure which naturally inhibits medication binding. Smoker...

The Gab2–MALT1 Axis Regulates Thromboinflammation & DVT

Oct 18, 2022

The third most prevalent cause of cardiovascular death is deep vein thrombosis (DVT). According to a number of studies, DVT develops when the inflammasome is activated, and the cytokine interleukin-1...

Proteomic & Phosphoproteomic Landscapes of AML

Oct 18, 2022

For a study, researchers created a deep-scale proteome and phosphoproteome database using 6 healthy bone marrow-derived controls and 44 representative acute myeloid leukemia (AML) patients from the LA...

KIR3DL2: Acute ATL Typing & Potential Therapeutic Target

Oct 18, 2022

The lymphoid tumor known as adult T-cell leukemia (ATL) is brought on by human T-cell leukemia virus type 1 (HTLV-1), which produces the transcriptional activator Tax that aids in the immortalization ...

Cytoplasmic UBA1 Contributes to VEXAS Syndrome Pathogenesis

Oct 18, 2022

Vacuoles, E1 ubiquitin-activating enzyme, X-linked, autoinflammatory somatic (VEXAS) syndrome, an adult-onset inflammatory illness with overlapping hematologic symptoms, is caused by somatic mutations...

Ticagrelor vs Placebo for the Reduction of Vaso-occlusive Crises in Pediatric SCD

Oct 18, 2022

The reversible P2Y12 inhibitor ticagrelor was compared to a placebo in phase 3 HESTIA3 research to see how well it prevented vaso-occlusive crises in young sickle cell disease (SCD) patients. Weigh...

TRX518 GITR Antibody: Gemcitabine, Pembrolizumab, Nivolumab

Oct 18, 2022

Glucocorticoid-induced TNF receptor-related protein (GITR) is the target of the monoclonal antibody TRX518. In advanced solid tumors, the safety and effectiveness of TRX518 monotherapy and in combinat...

BET Inhibitor GS-5829 as Monotherapy & Combined with Enzalutamide in mCRPC Patients

Oct 18, 2022

Safety and efficacy of the oral bromodomain and extraterminal inhibitor GS-5829, both alone and in combination with enzalutamide, in patients with metastatic castration-resistant prostate cancer (mCRP...

DIPG Upfront Biology-Guided Therapy: PNOC003 Outcomes

Oct 17, 2022

In PNOC003, children and young people with a recent diagnosis of diffuse intrinsic pontine glioma (DIPG) will participate in a multi-center precision medicine trial. Patients were enrolled between the...

Adding Umbralisib & Ublituximab to Ibrutinib in CLL Patients

Oct 17, 2022

Although toxicity and resistance have restricted ibrutinib's application, the drug has revolutionized the treatment of chronic lymphocytic leukemia (CLL). Patients with detectable MRD who had previous...

TTE Endpoints in Oncology Clinical Trials: CAR-T Therapy

Oct 17, 2022

The topic of cancer immunology has seen a surge of attention in recent years because of the promising potential of chimeric antigen receptor T-cell (CAR-T) treatment. To evaluate the effectiveness of ...

Cancer Immunoediting in the Era of Immuno-oncology

Oct 17, 2022

Developments in the understanding of T-cell biology and immune-tumor cell interactions have ushered in a new age in cancer immunotherapy. In its most sophisticated form, cancer goes through 3 phases c...

Circulating Tumor DNA–Based MRD Assessment in CLL Patients

Oct 14, 2022

Minimal residual disease (MRD) assessment has emerged as an important indicator of therapy efficacy and a surrogate for progression-free survival in chronic lymphocytic leukaemia (CLL) due to the emer...

Lung Cancer Patients: Handgrip Weakness, Inflammation Indicators, & OS

Oct 14, 2022

In several malignancies, the likelihood of death has been predicted using systemic inflammation and hand grip weakening. For a study, researchers sought to assess the relationship between handgrip wea...

CEACAM6 as a Biomarker for Leptomeningeal Metastasis in LUAD

Oct 14, 2022

Leptomeningeal metastasis (LM) is difficult to diagnose. CEACAM6 mRNA was discovered to be substantially elevated in the cerebrospinal fluid (CSF) of patients with lung adenocarcinoma with LM (LUAD-LM...

Apatinib Plus Chemotherapy in Advanced SCLC: Phase II Study

Oct 14, 2022

After first-line platinum-based chemotherapy fails, patients with small-cell lung cancer (SCLC) have only a limited number of alternatives for treatment. For a study, researchers sought to assess the ...